The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

The deferral affects B. Riley’s 6.875% Series A and 7.375% Series B preferred stock, according to a statement Monday. Dividends on those preferreds cost the company $2 million in the second ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.13% of ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...

Research analysts at B. Riley boosted their FY2024 earnings per share (EPS) estimates for Gentex in a report issued on Tuesday, January 21st. B. Riley analyst J. Nichols now anticipates that the auto ...